Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

NCT ID: NCT01344954

Last Updated: 2012-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

632 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prophylaxis of Venous Thromboembolic Events

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

25mg TB-402

Group Type EXPERIMENTAL

TB-402

Intervention Type DRUG

Administered intravenously over 10 minutes

50mg TB-402

Group Type EXPERIMENTAL

TB-402

Intervention Type DRUG

Administered intravenously over 10 minutes

10mg QD Rivaroxaban

Group Type ACTIVE_COMPARATOR

Rivaroxaban

Intervention Type DRUG

Administered orally as a capsule once a day for 35 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TB-402

Administered intravenously over 10 minutes

Intervention Type DRUG

Rivaroxaban

Administered orally as a capsule once a day for 35 days

Intervention Type DRUG

TB-402

Administered intravenously over 10 minutes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xarelto

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects aged ≥ 18 years.
2. Written informed consent.
3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

Exclusion Criteria

1. Pregnancy at the time of screening.
2. Indication for anticoagulation other than post-operative thromboprophylaxis.
3. Active bleeding or high risk of bleeding.
4. Anticipated continued use of neuraxial catheter after surgery.
5. Clinical laboratory findings at screening of thrombocytopenia or prolonged aPTT or PT.
6. Uncontrolled hypertension.
7. Impaired liver function (transaminase \>3 X ULN) or history of hepatic insufficiency.
8. Creatinine clearance \<30 mL/min.
9. Antiplatelet agents other than low dose aspirin (\< 200mg).
10. The use of intermittent pneumatic compression.
11. Known hypersensitivity to contrast media or rivaroxaban.
12. Known drug or alcohol abuse.
13. Active malignant disease or current cytostatic treatment.
14. Stroke within the previous month.
15. Participation in an investigational drug study within the past 30 days or previous participation in this study.
16. Any condition that in the opinion of the investigator would put the subject at increased risk from participating in the study or expected inability to comply with the protocol.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioInvent International AB

INDUSTRY

Sponsor Role collaborator

ThromboGenics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KRANKENHAUS DES BARMHER.SCHW.Linz

Linz, , Austria

Site Status

AKH Wien

Vienna, , Austria

Site Status

Orthopädisches Spital Speising

Vienna, , Austria

Site Status

Klinikum Wels-Grieskirchen GmbH

Wels, , Austria

Site Status

ZNA Antwerpen Locatie Middelheim

Antwerp, , Belgium

Site Status

SHAT of orthopedics, traumatology and surgery "Sv. Pantaleimon " - Pleven Department of Orthopaedics and Traumatology

Pleven, , Bulgaria

Site Status

Department of Orthopedics, UMHAT "Sv. Georgi"

Plovdiv, , Bulgaria

Site Status

MHAT Rousse, Department of Orthopaedics

Rousse, , Bulgaria

Site Status

UMHAT "St Anna" AD,Clinic of Orthopaedics and Traumatology

Sofia, , Bulgaria

Site Status

UMHAT 'Tsaritsa Joanna'

Sofia, , Bulgaria

Site Status

Pándy Kálmán Kórház

Gyula, , Hungary

Site Status

Bács-Kiskun Megyei Önkormányzat Kórháza, Szegedi Tudományegyetem Általános Orvostudományi Karháza

Kecskemét, , Hungary

Site Status

Tolna Megyei Önkormányzat Balassa János Kórháza

Szekszárd, , Hungary

Site Status

Traumatology and Orthopedics Clinic "Adazi", LTD

Ādaži, , Latvia

Site Status

Ltd "Liepajas regionala slimnica"

Liepāja, , Latvia

Site Status

Riga 2nd Hospital

Riga, , Latvia

Site Status

Ltd "Vidzemes slimnica"

Valmiera, , Latvia

Site Status

Diaconessenhuis Leiden

Leiden, , Netherlands

Site Status

Klinika Orthopedii I Traumatologii

Bialystok, , Poland

Site Status

Wojewódzkie Centrum Ortopedii i Rehabilitacji Narządu Ruchu im. dr Z. Radlińskiego w Łodzi

Lodz, , Poland

Site Status

NZOZ Szpital w Puszczykowie

Puszczykowo, , Poland

Site Status

Klinika Ortopedii, WIM

Warsaw, , Poland

Site Status

Medical University of warsaw, Dept of Orthopaedics

Warsaw, , Poland

Site Status

Municipal Healthcare Institution "City Clinical Hospital No. 3"

Chelabinsk, , Russia

Site Status

Municipal Healthcare Medical Institution "City Clinical Hospital No. 4"

Orenburg, , Russia

Site Status

Federal State Healthcare Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency of Russia

Saint Petersburg, , Russia

Site Status

Saint Petersburg State Healthcare Institution "City Aleksandrovskaya Hospital"

Saint Petersburg, , Russia

Site Status

Saint Petersburg State Healthcare Institution "Municipal Multi-Speciality Hospital No. 2"

Saint Petersburg, , Russia

Site Status

State Healthcare Institution "Samara Regional Clinical Hospital n.a. M.I. Kalinin"

Samara, , Russia

Site Status

Municipal Healthcare Institution "Clinical Hospital of Emergency Care n.a. N.V. Soloviov"

Yaroslavl, , Russia

Site Status

Public Entity "Regional Hospital - Center of Emergency Medical Care and Disaster Medicine" of Cherkasy Regional Council, Department of orthopedy and traumatology

Cherkassy, , Ukraine

Site Status

Ivano-Frankіvsk Regional Clinical Hospital MoH Ukraine, Department of ortopedics and traumatology. Department of traumatology, ortopedics and military/emergency surgery of Ivano-Frankіvsk National Medical University

Ivano-Frankivsk, , Ukraine

Site Status

SE "Sytenko Institute of Spine and Joint Pathology, AMS Ukraine", department of orthopedic arthrology and endoprosthesis replacement

Kharkiv, , Ukraine

Site Status

Public Entity of Kyiv Regional council "Kyiv Regional Clinical Hospital", Ortopedy and traumatology center of Public Entity of Kyiv Regional council "Kyiv Regional Clinical Hospital"

Kyiv, , Ukraine

Site Status

Public Establishment "Odessa Regional Clinical Hospital", Department of Orthopedics and Traumatology.

Odesa, , Ukraine

Site Status

Public Establishment 'City Hospital #9', orthopedy and traumatology department

Sevastopol, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Bulgaria Hungary Latvia Netherlands Poland Russia Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TB-402-006

Identifier Type: -

Identifier Source: org_study_id